UBS Group
MENS

UBS Group’s Jyong Biotech MENS Stock Holding History

UBS Group’s Portfolio MENS Stock Details MENS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.38K Sell
4,046
-33,317
-89% -$70.7K ﹤0.01% 8685
2026
Q1 		$80.3K Sell
37,363
-108,285
-74% -$265K ﹤0.01% 7101
2025
Q4 		$575K Buy
145,648
+145,111
+27,023% +$5.12M ﹤0.01% 5995
2025
Q3 		$21.1K Buy
+537
New +$19.3K ﹤0.01% 8117

Other funds holding MENS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
SOW
State of Wyoming Cheyenne, Wyoming $989M AUM 52.24% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

UBS Group's MENS Position: Q2 2026 in Review

UBS Group reduced its Jyong Biotech (MENS) stake by 89% in Q2 2026, selling an estimated $70.7K and leaving 4,046 shares worth $8.38K. The position accounts for ﹤0.01% of the portfolio, ranked #8685.

UBS Group first reported a position in MENS in Q3 2025 and has held it in 4 quarters since. The position peaked at $575K in Q4 2025. 19 funds tracked by Wall St. Rank hold MENS as of Q2 2026.

  • UBS Group held 4,046 shares of Jyong Biotech worth $8.38K as of Q2 2026.
  • UBS Group sold 33,317 Jyong Biotech shares in Q2 2026, an estimated $70.7K.
  • Jyong Biotech made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8685 holding.
  • UBS Group first reported a position in Jyong Biotech in Q3 2025 and has held it in 4 quarters since.
  • UBS Group's Jyong Biotech position peaked at $575K in Q4 2025.
  • 19 funds tracked by Wall St. Rank held Jyong Biotech as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.